sinomed

What sinomed does

SINOMED (Sino Medical Sciences Technology Inc., 赛诺医疗科学技术股份有限公司) is a China-based, publicly traded interventional medical device company founded in 2007 and headquartered in Tianjin. Listed on the Shanghai STAR Market (688108.SH) since October 2019, the company develops drug-eluting stents and structural heart devices for treating coronary, neurovascular, and structural heart disease. Its core technology platform centers on healing-targeted drug elution kinetics combined with its proprietary eG™ electrochemical coating process, which produces a filament-like coating structure that interdigitates with the polymer matrix to resist flaking and cracking. Key products include the HT Supreme® coronary drug-eluting stent (90% drug release within 28 days), the NOVA NEO™ intracranial drug-eluting stent (positioned as the world's first for neuro-interventional treatment), and the ACCUFIT™ transapical mitral valve replacement system in development.

The company operates a sales-led go-to-market model targeting hospitals, cardiac centers, and neuro-interventional centers through direct institutional sales. SINOMED has executed a European commercial launch of HT Supreme and holds CE Mark approval with expanded indications for use. Revenue is generated through hardware sales of medical devices procured by healthcare institutions, with pricing not publicly disclosed. The company has grown from a 30-person startup with sub-10M RMB revenue to 500+ employees and over 400M RMB annual income (2019 figure), and is recognized as one of the leaders in the Chinese coronary stent market. Strategic clinical collaborations, including with National University of Ireland Galway, support multi-jurisdiction evidence generation for regulatory approvals and commercial expansion across European, US, and Japanese markets.

Name

sinomed

Legal name

Sino Medical Sciences Technology Inc.

Website

https://sinomed.com

Company type

Public

Founded year

2007

Operating status

Ipo

Headcount range

501–1,000 employees

Short description

SINOMED is a China-based, publicly traded medical device company (688108.SH) developing drug-eluting stents and structural heart devices for hospitals and cardiac centers across coronary, neurovascular, and structural heart disease treatment.

Ownership category

akta.pro rank

Product category

Interventional Cardiology Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Coronary Stents & Drug-Eluting Technologies (HLAHAFAA)

akta.pro secondary industries

Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB), Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

Keywords

• Drug-eluting stents
• Interventional cardiology devices
• Neurovascular stents
• Transcatheter heart valves
• Coronary intervention products

Headquarters

HQ city

Tianjin

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales: SINOMED generates revenue through the sale of interventional medical devices including coronary stents, neurovascular stents, and structural heart products. The company is publicly traded on Shanghai STAR Market (688108.SH).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

SINOMED develops, manufactures, and commercializes interventional medical devices for the treatment of coronary artery disease, neurovascular disease, and structural heart disease. Core offerings include drug-eluting coronary stents (HT SUPREME®, BuMA Supreme), the NOVA NEO™ intracranial drug-eluting stent, and the ACCUFIT™ transcatheter mitral valve replacement system. The company ties these products together through a proprietary healing-targeted drug elution and eG™ electrochemical coating platform.

Product overview

SINOMED offers a portfolio of pioneering medical devices for interventional medicine, focusing on three main product categories: CORONARY INTERVENTION (HT SUPREME® Drug Coated Coronary Stent System, BuMA Supreme, NC Thonic®, Tytrak®), NEURO INTERVENTION (NOVA NEO™ Intracranial Drug-eluting Stent System), and STRUCTURAL HEART (ACCUFIT™ Transapical Mitral Valve Replacement System). The company's Healing-Targeted technology platform underpins its drug eluting stents, featuring biodegradable polymers and specialized coatings designed to enable natural healing through controlled elution kinetics.

Differentiator

Problem solved

Functional benefit

Brands

• HT SUPREME: Healing-Targeted Drug Eluting Stent designed specifically to allow natural healing through elution kinetics, biodegradable polymer and specialized coating.
• NOVA NEO
• ACCUFIT

Products and services

• HT SUPREME® Drug Coated Coronary Stent System Healing-Targeted Drug Eluting Stent designed for coronary intervention, featuring biodegradable polymer and specialized coating that enables natural healing through elution kinetics, with 90% of drug released within 28 days to enable faster return of the protective endothelial layer. Sold to hospitals and cardiac centers performing interventional cardiology procedures. CE Mark approved with expanded one-month DAPT IFU guidance for all-comer patients.
• NOVA NEO™ Intracranial Drug-eluting Stent System World's first drug-eluting stent and first healing-targeted stent devoted to neuro-interventional treatment. Features unique drug coating design allowing rapid functional healing of the endothelial layer, reducing risk of restenosis and stroke. Targeted at medical centers performing neurointerventional procedures for cerebrovascular disease.
• ACCUFIT™ Transapical Mitral Valve Replacement System Transapical Mitral Valve Replacement System for minimally invasive mitral valve replacement. Features unique self-expanding valve body design for optimal native valve 'clipping' effect and unique sealing ring design to minimize paravalvular leakage. Product in development; targeted at cardiac centers offering minimally invasive valve replacement procedures.
• BuMA Supreme Coronary Drug-Eluting Stent Coronary drug-eluting stent system referenced in the PIONEER-III clinical trial for European, US, and Japanese markets. Sold to hospitals and interventional cardiology providers.

Quantifiable outcome

• 90% of drug released within 28 days
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• National University of Ireland GalwaycoreStrategic or Co-development Partner · 5 July 2021Clinical collaboration to evaluate a non-invasive assessment method for stenting. This partnership supports SINOMED's clinical program and generates evidence for device approvals and performance outcomes.

Scale indicators4 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• Medtronic: Operator of the Resolute Onyx DES franchise and a leading structural heart player (Intrepid TMVR program). Directly competes with SINOMED in coronary DES and mitral valve replacement categories.
• Stryker: Operates a neurovascular intervention business (acquired through the Wright/Certalfi and prior acquisitions) alongside broader surgical and orthopedic portfolios. Comparable for SINOMED's NOVA NEO neuro-interventional franchise.
• Edwards Lifesciences: Global leader in structural heart with the SAPIEN TAVR platform and active TMVR programs. Directly comparable for SINOMED's ACCUFIT mitral valve program and provides structural-heart benchmarking.
• B. Braun: German medical device company with coronary intervention products (Coroflex ISAR DES) and a broad surgical/ interventional portfolio. Comparable broad incumbent competing in coronary DES and adjacent interventional cardiology.
• Boston Scientific: Global interventional cardiology leader with the PROMUS/Promus PREMIER drug-eluting stent franchise. Competes directly with SINOMED's HT SUPREME in DES and operates across peripheral and structural heart, making it a benchmark broad incumbent.
• Terumo: Japanese-headquartered medical device company with a significant interventional cardiology business (Ultimaster DES). Operates broadly across the cardiovascular space with comparable DES technology and clinical positioning.
• Abbott: Through Abbott Vascular, competes in coronary DES (XIENCE family) and is a global leader in vascular intervention. Comparable as a broad incumbent across SINOMED's coronary and peripheral vascular portfolio.

Emerging players

• Penumbra: Neurovascular intervention company focused on stroke treatment (thrombectomy and access). Comparable to SINOMED's NOVA NEO intracranial DES initiative as an adjacent neurovascular intervention player.

Direct peers

• MicroPort Scientific: Shanghai-listed interventional device company with the Firehawk and Firebird DES franchises. Directly comparable Chinese peer competing in coronary stents and adjacent cardiovascular categories.
• Lepu Medical: Chinese interventional medical device company and direct domestic competitor in coronary drug-eluting stents. Competes head-to-head with SINOMED in China's VBP-driven coronary stent market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/sinomed

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about sinomed